Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
March 11, 2022 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
March 08, 2022 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
March 03, 2022 09:20 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
February 24, 2022 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to...
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
February 17, 2022 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing...
Worldwide Uveitis Treatment Industry to 2026 - Key Motivators, Restraints and Opportunities
February 22, 2021 05:43 ET
|
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global uveitis treatment market is projected...
Trivedi Global, Inc. and Su-Mei Liu Announce Research Results on the Impact of a Biofield Energy Treated Nutraceutical for Decreasing Inflammation and Autoimmune Disorders
May 29, 2018 17:54 ET
|
Trivedi Global, Inc.
Oakland, CA, May 29, 2018 (GLOBE NEWSWIRE) -- Su-Mei Liu, an evidence-based energy healer, today announces research based on the impact of a biofield energy treated nutraceutical to improve overall...
Cyrex Array 2 Provides Clinicians Cutting-Edge Technology for Accurate Assessment and Monitoring of Intestinal Barrier Function
July 13, 2016 10:00 ET
|
Cyrex Laboratories
PHOENIX, AZ--(Marketwired - July 13, 2016) - Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, offers Array 2, an intestinal antigenic permeability...